Big pharma's rare disease adventure worries small biotech
This article was originally published in Scrip
Pharma's recent interest into rare and orphan diseases has raised fears of price exploitation among smaller companies such as Trophos, which develops drugs for rare neurodegenerative disease. Speaking to Scrip last week at the BioPartnering Europe meeting in London, Dr Damian Marron, CEO of Trophos, expressed concerns that the recent deal muscle-flexing in rare diseases by firms such as Pfizer, GlaxoSmithKline and Sanofi-Aventis would "muddy the waters". He believes that, in order to recoup its outlays on deals and acquisitions in rare diseases, big pharma is likely to pursue a high-risk/high-margin strategy, charging high prices for treatments needed by patients often suffering from debilitating and severe diseases such as ALS.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.